IFW)

NOV 2 1 2006 W

Typed or printed name

40B	j				U.S. F	Patent and 1	PTO/SB/2 Approved for use through 03/31/2007. OMB 06 Trademark Office; U.S. DEPARTMENT OF COM	651-0031 MMERCE		
06 4	Inder the Par	perwork Re	eduction Act of 1995	no person	s are required to respond to a col Application Number	10/519	nformation unless it displays a valid OMB control	number.		
	TRANSMITTAL				Filing Date		-			
	ıĸ				First Named Inventor	<u> </u>	July 2, 2003			
FORM /					Art Unit	1614	Etcheberrigaray			
					Examiner Name	·				
(to be used for all correspondence after initial filing)						Not Y	Yet Assigned			
Tota	Total Number of Pages in This Submission				Attorney Docket Number	17357	7.01001US	/		
				ENCI	OSURES (Check all	that apply				
	Fee Transmittal Form				Orawing(s)	After Allowance Communication to				
	Fee Attached			<u></u> ι	icensing-related Papers		Appeal Communication to Boar of Appeals and Interferences	·d		
	Amendment/Reply				Petition		Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)	ð		
1	After Finat				Petition to Convert to a		Proprietary Information	•		
	$\overline{\Box}$			Provisional Application Power of Attorney, Revocation			Status Letter			
	Affidavits/declaration(s)			Change of Correspondence Address  Terminal Disclaimer			Other Enclosure(s) (please ider	ntify		
	Extension of Time Request  Express Abandonment Request						below):	-		
					Request for Refund					
	Information Disclosure Statement			CD, Number of CD(s)						
				Landscape Table on CD						
	Certified Copy of Priority Document(s)			Remarks  1. Request for Corrected Filing Receipt						
	Reply to N			Copy of Official Filing Receipt with corrections						
	Incomplete Application Reply to Missing Parts			2. Copy of Official Pilling Receipt with corrections						
	∟∐ ur	nder 37 C	FR 1.52 or 1.53							
			SIGNA	TURE C	F APPLICANT, ATTO	RNEY, C	OR AGENT			
Firm N	lame	Milba	nk, Tweed, I	Hadley	& McCloy LLP					
Signati	ure	En	igue Lo	notin						
Printed	Printed name Enrique D. Longto									
Date	November 21, 200		06 Reg. No.			47,304				
			C	ERTIFIC	ATE OF TRANSMISSI	ION/MA	AILING			
Lhereb	ov certify the	at this co	rrespondence is h	eing facsi	mile transmitted to the USPT	O or depo	osited with the United States Postal Service	e with		
sufficie	ent postage	as first c					, P.O. Box 1450, Alexandria, VA 22313-14			
Signati	te shown be ure	elow:	·		. 200					

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)
Rene Etcheberrigaray et al.	) Group Art Unit: 1614
Patent Application No. 10/519,110	) Examiner: Not Yet Assigned
Filed: July 2, 2003	)
For: PKC Activation As A Means For Enchancing sAPPa Secretion and Improving Cognition Using Bryostatin Type Compounds	) ) ) )
Commissioner of Patents United States Patent and Trademark Office P.O. Box 1450	

# REQUEST FOR CORRECTED FILING RECEIPT

Sir:

Applicants respectfully request correction of the Filing Receipt (Confirmation No. 9509) issued on November 8, 2006. Specifically, please change the following:

Name of Assignee

from "Blanchette Rockefeller Neurosciens Instiute" to

Blanchette Rockefeller Neurosciences Institute"; and

Title of Invention:

from **Pkc** activation as a means for enhancing **sappa** secretion and improving cognition using byrostatin type compounds" to "**PKC** activation as a means for enhancing **sAPP** alpha secretion and improving cognition using bryostatin type

compounds".

Respectfully submitted,

MILBANK, TWEED, HADLEY & MCCLOY LLP

Dated: November 21, 2006

Alexandria, VA 22313-1450

Enrique D. Dongton

Customer No. 000038647 Milbank, Tweed, Hadley & McCloy LLP International Square Building

International Square Building 1825 Eye Street, N.W., Suite 1100 Washington, D.C. 20006

Telephone: (202) 835-7500 Facsimile: (202) 835-7586



# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS PO. Box 1450 Alexandria, Viginia 22313-1450 www.uspib.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/519,110	02/03/2006	1614	1290	17357.01001US	16	49	3

**CONFIRMATION NO. 9509** 

FILING RECEIPT

\*OC000000021148525\*

38647 MILBANK, TWEED, HADLEY & MCCLOY LLP INTERNATIONAL SQUARE BUILDING 1850 K STRET, N.W., SUITE 1100 -WASHINGTON, DC 20006

Date Mailed: 11/08/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Rene Etcheberrigaray, Bethesda, MD; Daniel L. Alkon, Bethesda, MD;

**Assignment For Published Patent Application** 

Institute

Blanchette Rockefeller Neurosciences Instituté, Bethesda Maryland, MD

Power of Attorney: The patent practitioners associated with Customer Number 38647.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/US03/20820 07/02/2003 which claims benefit of 60/392,951 07/02/2002

Foreign Applications

If Required, Foreign Filing License Granted: 11/07/2006

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is US10/519,110

Projected Publication Date: 02/15/2007

Non-Publication Request: No

Early Publication Request: No

\*\* SMALL ENTITY \*\* PKC activation as a means for enhancing sAPP alpha secretion and improving cognition using bryostatin type compounds

Title

Pice activation as a means for enhancing sappa secretion and improving cognition using bryostatin type compounds

**Preliminary Class** 

514

## PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

#### **GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier